Helen Torley, President and CEO of HALOZYME THERAPEUTICS, INC. (NASDAQ:HALO), recently sold 50,000 shares of the company’s common stock for a total of approximately $3.37 million. These transactions occurred between June 1 and June 3, 2026, with shares sold at prices ranging from $66.314 to $69.692. The stock currently trades at $69.85, up nearly 30% over the past year, though InvestingPro analysis suggests the company remains undervalued relative to its Fair Value.
The sales followed Ms. Torley’s exercise of stock options, through which she acquired 50,000 shares of common stock at a price of $12.07 per share, amounting to $603,500. All these transactions were executed under a pre-arranged Rule 10b5-1 trading plan, which Ms. Torley established on March 21, 2025. The options exercised were part of a grant from February 22, 2017, and are set to expire in February 2027.
Following these reported activities, Ms. Torley directly holds 767,780 shares of Halozyme Therapeutics common stock. She also retains 1,923 derivative shares in the form of options to purchase common stock. The company, valued at $8.28 billion, maintains a "GREAT" financial health score on InvestingPro, which offers 10 additional ProTips and a comprehensive Pro Research Report for deeper analysis.
In other recent news, Halozyme Therapeutics reported strong financial results for the first quarter of 2026, surpassing Wall Street expectations. The company achieved an earnings per share (EPS) of $1.60, exceeding the projected $1.54, and reported revenue of $377 million, outperforming the forecast of $358.45 million. These results reflect a 3.9% and 5.18% surprise in earnings and revenue, respectively. Citizens reiterated its Market Outperform rating on Halozyme, highlighting the company’s strong start to 2026 and long-term revenue drivers beyond 2029. Benchmark also maintained its Buy rating with a $90 price target, emphasizing the company’s long-term potential despite investor concerns over the 2022 Inflation Reduction Act and patent litigation with Merck. Analyst Robert Wasserman from Benchmark noted these issues weigh on sentiment, but the overall outlook remains positive. These developments indicate continued confidence in Halozyme’s growth trajectory.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Most traders can read a chart. The hard part is the moment: entry window open, pattern forming, and you're still waiting for more confirmation. That's the conviction gap — and our chart analysis closes it. Unlike other AIs that just read data, our Vision AI literally "sees" your charts and hands you a complete trading plan: entry, stop-loss, and profit target in under 60 seconds. Know exactly what to do next, every time.